AstraZeneca says its antibody treatment for people exposed to coronavirus is not effective
The results of the treatment were ‘not statistically significant’ said the drugmaker
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca says its antibody treatment for Covid-19 does not prevent symptoms in people who have been exposed to the virus.
The drug maker announced on Tuesday its treatment, called AZD7442, reduced the risk of developing symptomatic Covid by 33 per cent, compared to the placebo, but that this was not statistically significant.
Trial participants were adults over the age of 18 with confirmed exposure to a person who had coronavirus within the past eight days.
Mene Pangalos, executive vice president of BioPharmaceuticals R&D, at the company said in a statement: “While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442.”
AZD7442 is currently being tested in several other Covid-19 prevention and treatment trials, the company said.
The full results from the trial, called Storm Chaser, will be submitted for publication in a peer-reviewed medical journal.
The company had previously agreed a deal with with the US Government to supply up to 500,000 doses of AZD7442 for $205m (£145m).
Discussions regarding next steps with the US Government are ongoing, the company confirmed.
Myron J Levin, professor of pediatrics and medicine at the University of Colorado School of Medicine, who was the principal investigator on the trial, said the drug could be effective in preventing Covid in people who have not yet been infected.
He added: “While Covid-19 vaccination efforts have been successful, there is still a significant need for prevention and treatment options for certain populations, including those unable to be vaccinated or those who may have an inadequate response to vaccination.”
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments